Advancing Cell Therapy for Vision Loss The field of regenerative medicine has taken an exciting step forward. Recently, BlueRock Therapeutics, a subsidiary of Bayer, announced positive updates regarding their investigational cell therapy, lemiretprocel (OpCT-001). This therapy is specifically designed to address the challenges of vision loss caused by retinal degeneration. Understanding the Science Lemiretprocel is…